Quantcast
Last updated on April 18, 2014 at 7:29 EDT

Latest Joint Project Manager Transformational Medical Technologies Stories

2013-01-14 12:20:46

ALEXANDRIA, Va., Jan. 14, 2013 /PRNewswire/ -- The Tauri Group, LLC is pleased to announce that it has been selected as the prime contractor to provide Advisory & Assistance Services (A&AS) for the Joint Project Manager Transformational Medical Technologies (JPM-TMT). The task order contract has a value of $49 million over the next three years. The Joint Project Manager for Transformational Medical Technologies (JPM-TMT) employs innovative technologies and non-traditional approaches...

2012-10-02 10:22:16

JPM-TMT's Strategy in Accordance with Original RFP FORT BELVOIR, Va., Oct. 2, 2012 /PRNewswire-USNewswire/ -- The Department of Defense's (DoD) Joint Program Executive Office for Chemical and Biological Defense, Joint Project Manager Transformational Medical Technologies (JPM-TMT), completed a comprehensive evaluation of its Ebola medical countermeasure (MCM) candidate development efforts and decided that the Hemorrhagic Fever Virus (HFV) program will continue with only one of two...

2012-09-06 06:20:14

Sarepta Therapeutics, Inc. Will Investigate feasibility of Delivery via Intramuscular Route FORT BELVOIR, Va., Sept. 6, 2012 /PRNewswire-USNewswire/ -- A contract to evaluate an alternative method for delivering a medical countermeasure (MCM) was awarded to Sarepta Therapeutics by the Joint Project Manager Transformational Medical Technologies (JPM-TMT). A component of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), JPM-TMT has made significant...

2012-08-02 06:24:47

Treatment with JPM-TMTFunded AVI-7288 Shows Significant Survival Rates Even When Administered up to Four Days Post Infection FORT BELVOIR, Va., Aug. 2, 2012 /PRNewswire-USNewswire/ -- A new study testing a drug candidate to treat Marburg virus demonstrated significant survival rates up to four days after exposure to the disease. Referred to as AVI-7288, the drug is a post-exposure prophylactic targeting the Marburg virus which may cause hemorrhagic fever, a severe, life-threatening...

2012-03-15 18:23:00

MediVector, Inc.'s Favipiravir (T-705) targets multiple influenza virus strains FORT BELVOIR, Va., March 15, 2012 /PRNewswire-USNewswire/ -- The Department of Defense's (DOD) Joint Project Manager Transformational Medical Technologies (JPM-TMT) awarded a $138.5M contract to MediVector, Inc. to further develop Favipiravir (T-705), a broad-spectrum therapeutic against multiple influenza viruses, including the 2009 H1N1 pandemic virus and drug resistant influenza strains. The contract...